Ascletis Pharma Inc.

Investors

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Proposed Share Repurchase under the Repurchase Mandate
2025-10-02
Grant of Share Options
2025-09-30
Interim Report 2025
2025-09-29
Next Day Disclosure Return - Others
2025-09-23
Voluntary Announcement - Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
2025-09-22
Next Day Disclosure Return - Others
2025-09-18
Voluntary Announcement - Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
2025-09-18
Voluntary Announcement - Ascletis Presented Results from Cohorts 1 and 2 of 28-Day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
2025-09-17
Next Day Disclosure Return - Others
2025-09-12
Voluntary Announcement - Voluntary Lock-up Undertaking Made by Controlling Shareholders
2025-09-12

3

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1